Oteseconazole Gets Priority Review for Recurrent Vulvovaginal Candidiasis
The NDA submission is supported by data from three phase 3 trials, which included 2 global studies and one US-focused study.
Fungal Infections
Early De-escalation to Fluconazole for Fluconazole-Susceptible Candidemia
Investigators conducted a study to determine outcomes following early de-escalation to fluconazole following echinocandin empirical treatment in patients with fluconazole-susceptible candidemia.
Secondary Bacterial and Fungal Infections in Hospitalized Patients With COVID-19
A team of researchers sought to identify the incidence, antimicrobial susceptibilities, and outcomes associated with bacterial and fungal secondary infections in a large cohort of patients with COVID-19.
Posaconazole Noninferior to Voriconazole for Primary Treatment of Invasive Aspergillosis
Study authors assessed the noninferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis.
High Prevalence of Antibiotic Resistance in Men Having Sex with Men
The goal of this study was to assess the impact of doxycycline PEP on M genitalium, an emerging pathogen among men who have sex with men that has rising rates of antibiotic resistance.
Clinical Guidance for the Diagnosis and Treatment of COVID-19-Associated Pulmonary Aspergillosis
The European Commission on Medical Mycology and International Society for Human and Animal Mycology released clinical guidance and research criteria for managing invasive pulmonary aspergillosis among patients with SARS-CoV-2.
Invasive Pulmonary Fungal Infection Risk in Severe SARS-CoV-2-Related Pneumonia
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
Global Epidemiology of Fungal Keratitis and Its Outcomes
Investigators analyzed data collected over more than 70 years to estimate the annual global incidence of this severe corneal infection.
Ibrexafungerp Gets Priority Review for Vulvovaginal Candidiasis
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Antifungal Prophylaxis in Hematological Disease or Hematopoietic Stem Cell Transplantation
Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.
- Loading...
Loading...
Next post in Mycoses
Loading... 
Loading...